IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10201641 B1

PDFFull Text
Date of Patent:
Feb. 12, 2019

Filed:

Oct. 19, 2015

Sustained release intraocular implants and methods for treating ocular vasculopathies

Applicant:

Allergan, Inc., Irvine, CA (US);

Inventors:

Glenn T. Huang, Fremont, CA (US);

Brittany Jackson, Fort Worth, TX (US);

James A. Burke, Santa Ana, CA (US);

Ton Lin, Mission Viejo, CA (US);

Patrick M. Hughes, Aliso Viejo, CA (US);

Larry A. Wheeler, Irvine, CA (US);

Rosy Sheng Donn, Saratoga, CA (US);

Assignee:

Allergan, Inc., Irvine, CA (US);

Attorney:

Laura L. Wine

Primary Examiner:

Kyle A Purdy

Int. Cl.
CPC ...
A61L 31/14 (2006.01); A61K 31/498 (2006.01); C08L 67/04 (2006.01); A61K 9/20 (2006.01); A61L 31/16 (2006.01); A61L 27/58 (2006.01); A61K 9/00 (2006.01); A61K 47/34 (2017.01); A61L 31/06 (2006.01);
U.S. Cl.
CPC ...
A61L 31/148 (2013.01); A61K 9/0051 (2013.01); A61K 9/204 (2013.01); A61K 31/498 (2013.01); A61K 47/34 (2013.01); A61L 27/58 (2013.01); A61L 31/06 (2013.01); A61L 31/16 (2013.01); C08L 67/04 (2013.01); A61L 2300/436 (2013.01); A61L 2300/604 (2013.01); Y02A 50/401 (2018.01);
Abstract

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

Find Patent Forward Citations

Loading…